Inclusion Criteria:

1. Patients must have histologically or cytologically confirmed recurrent or metastatic
solid tumours. All patients will have no meaningful therapies available to them
including hormone therapy, chemotherapy and targeted therapies. For the malignancies
that have no proven therapy, they can be enrolled without any prior systemic therapy.

2. Four weeks must have elapsed since prior chemotherapy, hormonal therapy, targeted
therapy, or radiation therapy. There is no restriction in the amount of bone marrow
previously radiated.

3. Recovery to baseline or, at most, grade 1 of all drug-related toxicities due to prior
chemotherapy, radiation, hormonal therapy, or molecular targeted therapy, except for
alopecia.

4. Age ≥ 18 years.

5. ECOG performance status ≤ 2 (Karnofsky ≥70%, see Appendix A).

6. Life expectancy of greater than 12 weeks.

7. Patients must have normal organ and marrow function as defined below:

- absolute neutrophil count ≥1,500/mcL

- hemoglobin ≥90 g/L

- platelets ≥100,000/mcL

- total bilirubin ≤1.5 X upper limit of normal (ULN)

- AST(SGOT) and ALT(SGPT) ≤2.5 X ULN or ≤ 5 X ULN in the presence of liver
metastases

- creatinine ≤1.5 X institutional upper limit of normal

8. Cardiac ejection fraction by MUGA scan or echocardiogram must be >50% for patients at
baseline.

9. The effects of DCA on the developing human fetus are unknown. For this reason and
because DCA can be teratogenic, women of child-bearing potential and men must agree
to use adequate contraception (e.g.: hormonal or barrier method of birth control,
abstinence) prior to study entry and for the duration of study participation. Should
a woman become pregnant or suspect she is pregnant while participating in this study,
she should inform her treating physician immediately.

10. Ability to understand the purpose of the study and the willingness to sign a written
informed consent document.

Exclusion Criteria:

1. Patients who have had chemotherapy, hormonal therapy, molecular targeted therapy, or
radiotherapy within 4 weeks prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 4 weeks earlier.

2. Patients may not be receiving any other investigational agents, chemotherapy,
immunotherapy, radiotherapy, or molecular targeted agents.

3. Patients with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that could confound the evaluation of neurologic and other adverse
events.

4. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to DCA.

5. Due to the possibility of peripheral sensorimotor neuropathy from DCA, the presence
of grade 2 or higher peripheral neuropathy due to prior medical condition (such as
multiple sclerosis), medications, or other etiologies.

6. Any psychological, familial, sociological, or geographical conditions that do not
permit medical follow-up and compliance with the study protocol.

7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements. Specifically, for patients who are taking either or both oral
hypoglycemics and insulin for diabetes mellitus will not be eligible as DCA in
combination with these agents may increase the risk of clinically significant
hypoglycemia, compromising patient safety.

8. Pregnant women are excluded from this study because DCA is an agent with the
potential for teratogenic or abortifacient effects. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with DCA, breastfeeding should be discontinued if the mother is treated with
DCA.

9. HIV-positive patients on combination antiretroviral therapy are ineligible because of
the potential for pharmacokinetic interactions with DCA. In addition, these patients
are at increased risk of lethal infections when treated with marrow-suppressive
therapy. Appropriate studies will be undertaken in patients receiving combination
antiretroviral therapy when indicated.

10. 5 years must have elapsed since the initial curative procedure for other
malignancies, except for in situ cervical cancer, basal cell carcinoma of the skin,
and localized prostate cancer after curative therapy such as surgery, or radiation.

11. History of malabsorption syndrome or substantial amount of small bowels or stomach
removed that may impair absorption of DCA.

12. Patients taking warfarin. Low dose or therapeutic dose of heparin or low molecular
weight heparin is allowed.